Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells 65,110 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 65,110 shares of the stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $59.22, for a total transaction of $3,855,814.20. Following the sale, the chief executive officer now directly owns 95,105 shares in the company, valued at $5,632,118.10. This represents a 40.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Andrew Dudum also recently made the following trade(s):

• On Monday, June 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.51, for a total transaction of $2,686,146.34.
• On Monday, June 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.76, for a total transaction of $7,272,488.52.
• On Friday, May 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.25, for a total transaction of $2,768,855.50.
• On Friday, May 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.40, for a total transaction of $7,482,616.80.
• On Tuesday, April 29th, Andrew Dudum sold 50,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.39, for a total transaction of $1,819,500.00.
• On Wednesday, April 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.04, for a total transaction of $1,022,338.40.

Hims & Hers Health Stock Up 3.1%

NYSE:HIMS traded up $1.85 during trading hours on Wednesday, reaching $61.09. 43,207,932 shares of the company's stock were exchanged, compared to its average volume of 21,448,835. The firm has a market capitalization of $13.67 billion, a price-to-earnings ratio of 88.54, a P/E/G ratio of 2.23 and a beta of 2.09. The company has a 50-day moving average of $47.00 and a 200 day moving average of $38.75. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. Hims & Hers Health's quarterly revenue was up 110.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.05 EPS. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Large investors have recently bought and sold shares of the business. Strs Ohio acquired a new stake in shares of Hims & Hers Health in the 1st quarter worth $1,469,000. Kilter Group LLC lifted its stake in shares of Hims & Hers Health by 1.0% in the 1st quarter. Kilter Group LLC now owns 43,989 shares of the company's stock worth $1,300,000 after acquiring an additional 450 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the 1st quarter worth $30,000. Intech Investment Management LLC lifted its stake in shares of Hims & Hers Health by 74.5% in the 1st quarter. Intech Investment Management LLC now owns 143,287 shares of the company's stock worth $4,234,000 after acquiring an additional 61,195 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company's stock worth $12,373,000 after acquiring an additional 78,543 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HIMS. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $61.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. Truist Financial dropped their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Piper Sandler reissued a "neutral" rating and issued a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, Leerink Partners increased their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $38.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.